Phosphinate ester-containing dyes having tunable properties and methods of making the same
US-2024239823-A1 · Jul 18, 2024 · US
Small molecule drug conjugates
US9884122B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9884122-B2 |
| Application number | US-201615226439-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 2, 2016 |
| Priority date | Feb 3, 2014 |
| Publication date | Feb 6, 2018 |
| Grant date | Feb 6, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A targeted therapeutic agent comprising a compound of formula I: B-L-D (I), wherein: B is a low molecular weight binding moiety for Carbonic Anhydrase IX (CAIX); D is a drug moiety; and L is a linker group that undergoes cleavage in vivo for releasing said drug moiety in an active form. The drug moiety is suitably a cytotoxic agent for targeted delivery to cancer cells expressing CAIX. The binding moiety B suitably comprises a sulfonamidothiadiazole moiety. The binding moiety B may comprise one, two or more groups capable of binding to CAIX. The linker group suitably comprises a disulfide bond and/or a triazole group and/or a cleavable peptide group.
First claim
Opening claim text (preview).
The invention claimed is: 1. A ligand specific for CAIX having the formula: 2. The ligand of claim 1 , wherein said ligand comprises a radiolabel. 3. The ligand of claim 2 , wherein said radiolabel is Technetium. 4. A pharmaceutical composition comprising a targeted therapeutic agent comprising the ligand of claim 1 . 5. The pharmaceutical composition of claim 4 , wherein said ligand comprises a radiolabel. 6. The pharmaceutical composition of claim 5 , wherein said radiolabel is Technetium.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Dipeptides · CPC title
Isotopically modified compounds, e.g. labelled · CPC title
having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines · CPC title
Peptides; Proteins · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9884122B2 cover?
- A targeted therapeutic agent comprising a compound of formula I: B-L-D (I), wherein: B is a low molecular weight binding moiety for Carbonic Anhydrase IX (CAIX); D is a drug moiety; and L is a linker group that undergoes cleavage in vivo for releasing said drug moiety in an active form. The drug moiety is suitably a cytotoxic agent for targeted delivery to cancer cells expressing CAIX. The…
- Who is the assignee on this patent?
- Philochem Ag, Eth Zuerich
- What technology area does this patent fall under?
- Primary CPC classification A61K47/558. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).